Tuesday · November 17, 2026

 ·  Daily  ·  Newsletters

Resonance network: Quantum InsiderSpace Insider

Business & Markets · Startups

Remedy Robotics Raises $62M in Series B Funding to Advance AI-Enabled Vascular Intervention System

Insider Brief

  • Remedy Robotics raised $62 million in Series B funding to advance its AI-enabled N1 robotic system toward clinical trials and potential FDA approval for neurovascular procedures, including stroke treatment.
  • The DCVC-led round included UC Investments, Skip Capital, Hostplus and existing investors, with proceeds supporting a planned University of California clinical trial, prototype deployments and further development of autonomous capabilities.
  • The N1 System is designed for on-site, remote and autonomous endovascular procedures, but remains under development and is not approved for sale or clinical use in any jurisdiction.

Remedy Robotics has raised $62 million in Series B funding to advance an AI-enabled robotic system toward clinical trials and potential FDA approval for neurovascular procedures, including stroke treatment.

According to Remedy, the round was led by DCVC, with participation from new investors UC Investments, Skip Capital and Hostplus. Existing backers Build Collective, Blackbird, Divergent Capital and KdT Ventures also participated.

Remedy is developing its N1 System to perform endovascular procedures for neurovascular, coronary and peripheral vascular care, although the company’s initial regulatory efforts focus on neurovascular intervention. Co-founder and CEO Dr. David Bell said the funding will help speed up development and deployment of the N1 System to make specialized care more widely accessible, regardless of location.

“Endovascular intervention is the gold standard treatment for stroke and many cardiovascular emergencies, yet access remains limited to a small number of hospitals,” Bell pointed out. “For these time-critical conditions, that’s devastating. Even when specialist intervention is available, treatment is often delayed, and complications are frustratingly common.”

What’s Next?

Remedy said it plans to conduct a pivotal clinical trial in partnership with the University of California, deploy prototype N1 Systems through its clinical partners and continue developing the technology’s autonomous capabilities. The N1 System remains under development and is not currently available for sale or clinical use in any jurisdiction, the company noted.

According to Remedy, N1 uses machine learning to analyze medical images before procedures, simulate potential approaches and align three-dimensional and two-dimensional images in real time. The system is designed to perform entire endovascular procedures robotically, with options for on-site, remote or autonomous operation. Full autonomy remains under development, the company added.

Remedy said its technology could help expand access to specialized treatment for strokes and other cardiovascular emergencies, wirth the company citing research indicating that only 2.8% of eligible stroke patients worldwide have access to endovascular treatment.

In October 2025, Remedy reported completing what it described as the world’s first remote neurointerventional procedures using the N1 System. The company now works with more than 100 hospitals worldwide and plans to expand its clinical work through partnerships with SVIN Mission Thrombectomy and the Australian Stroke Alliance.

“This funding will allow our world-leading hardware, software, and machine learning teams to progress the N1 system towards clinical trials and potential FDA approval, while also developing additional features including full autonomy,” said Jake Sganga, CTO and co-founder of Remedy Robotics. “We are particularly excited to deepen our partnership with the University of California, having worked closely with their clinical experts since 2021, and as we prepare for our planned pivotal clinical trials to be held across the UC network.”

Greg Bock
About the author
Greg Bock

Greg Bock is an award-winning investigative journalist with more than 25 years of experience in print, digital, and broadcast news. His reporting has spanned crime, politics, business and technology, earning multiple Keystone Awards and a Pennsylvania Association of Broadcasters honors. Through the Associated Press and Nexstar Media Group, his coverage has reached audiences across the United States.

The AI economy, every weekday morning

The daily briefing plus the weekly Scale-ups to watch edition. Free, no spam, unsubscribe any time.